Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P A Pasanen

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Annales Chirurgiae Et Gynaecologiae|January 1, 1993
Pancreatic lymphomaP A Pasanen, M Eskelinen, M Vornanen, et al.
Anticancer Research|September 1, 1993
Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinomaP A Pasanen, M Eskelinen, K Partanen, et al.
Scandinavian Journal of Gastroenterology|August 1, 1993
Evaluation of a computer-based diagnostic score system in the diagnosis of jaundice and cholestasisP A Pasanen, P Pikkarainen, E Alhava, et al.
Anticancer Research|May 1, 1993
The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective studyP A Pasanen, R Kauppinen, M Eskelinen, et al.
In Vivo (Athens, Greece)|March 1, 1994
A prospective study on the value of ultrasound, computed tomography and endoscopic retrograde cholangiopancreatography in the diagnosis of unjaundiced cholestasisP A Pasanen, K Partanen, P Pikkarainen, et al.
Anticancer Research|November 1, 1992
A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patientsP A Pasanen, M Eskelinen, K Partanen, et al.
Anticancer Research|September 1, 1992
Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective studyP A Pasanen, M Eskelinen, K Partanen, et al.
British Journal of Cancer|May 1, 1992
Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinomaP A Pasanen, M Eskelinen, K Partanen, et al.
British Journal of Cancer|April 1, 1993
Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective studyP A Pasanen, M Eskelinen, K Partanen, et al.
Anticancer Research|November 1, 1995
Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancyP A Pasanen, M Eskelinen, K Partanen, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Annales Chirurgiae Et Gynaecologiae|January 1, 1993
Pancreatic lymphomaP A Pasanen, M Eskelinen, M Vornanen, et al.
Anticancer Research|September 1, 1993
Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinomaP A Pasanen, M Eskelinen, K Partanen, et al.
Scandinavian Journal of Gastroenterology|August 1, 1993
Evaluation of a computer-based diagnostic score system in the diagnosis of jaundice and cholestasisP A Pasanen, P Pikkarainen, E Alhava, et al.
Anticancer Research|May 1, 1993
The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective studyP A Pasanen, R Kauppinen, M Eskelinen, et al.
In Vivo (Athens, Greece)|March 1, 1994
A prospective study on the value of ultrasound, computed tomography and endoscopic retrograde cholangiopancreatography in the diagnosis of unjaundiced cholestasisP A Pasanen, K Partanen, P Pikkarainen, et al.
Anticancer Research|November 1, 1992
A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patientsP A Pasanen, M Eskelinen, K Partanen, et al.
Anticancer Research|September 1, 1992
Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective studyP A Pasanen, M Eskelinen, K Partanen, et al.
British Journal of Cancer|May 1, 1992
Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinomaP A Pasanen, M Eskelinen, K Partanen, et al.
British Journal of Cancer|April 1, 1993
Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective studyP A Pasanen, M Eskelinen, K Partanen, et al.
Anticancer Research|November 1, 1995
Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancyP A Pasanen, M Eskelinen, K Partanen, et al.
Pageof 2